Reporting of different areas pertaining to synovial tissue sampling, handling or analysing
| N | % | ||
| Clinical data | Age and RMDs | 26/26 | 100 |
| Disease duration | 24/26 | 92 | |
| Disease activity | 16/26 | 62 | |
| Treatments | 16/26 | 62 | |
| US features (if US-guided SB) | 4/11 | 36 | |
| Biopsy procedure | Target joint(s) | 21/26 | 81 |
| Operators’ experience | 0/24 | 0 | |
| Adverse events | 5/24 | 20 | |
| Tissue handling | Number of fragments | 19/26 | 73 |
| Processing: fixation, freezing, fresh use, specific processing details | 26/26 | 100 | |
| Tissue quality control | 17/26 | 65 | |
| Tissue outcomes | Imaging: scoring/quantification, area assessed | 25/26 | 96 |
| Reference to another publication for scoring system | 8/26 | 30 | |
| Intraobserver/interobserver reproducibility | 4/26 | 15 | |
| RNA/DNA: purity, quality, analysis | 4/10 | 40 | |
| Disaggregation: isolation method, purity and viability | 2/2 | 100 |
Green, 71–100%; Orange, 36–70%; Red, 0–35%; RMDs, rheumatic and musculoskeletal diseases; SB, synovial biopsy; US, ultrasound.